Patents by Inventor Ellen Codd

Ellen Codd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aminotetralin-derived urea modulators of vanilloid VR1 receptor
    Patent number: 8569505
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to ?-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: October 29, 2013
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Ellen Codd, Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
  • Quinoline-derived amide modulators of vanilloid VR1 receptor
    Patent number: 8394828
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: March 12, 2013
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Ellen Codd, Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
  • Tricyclic ?-opioid modulators
    Patent number: 8350041
    Abstract: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ?-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: January 8, 2013
    Assignee: Janssen Pharmaceutica, NV
    Inventors: John R. Carson, Ellen Codd, Christine M. Razler, Andrea Works, Mark McDonnell, James J. McNally
  • TRICYCLIC DELTA-OPIOID MODULATORS
    Publication number: 20120095010
    Abstract: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ?-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.
    Type: Application
    Filed: December 22, 2011
    Publication date: April 19, 2012
    Inventors: John R. Carson, Ellen Codd, Christine M. Razler, Andrea Works, Mark McDonnell, James J. McNally
  • Tricyclic ?-opioid modulators
    Patent number: 8106207
    Abstract: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ?-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: January 31, 2012
    Assignee: Janssen Pharmaceutica, NV
    Inventors: John R. Carson, Ellen Codd, Christine M. Razler, Andrea Works, Mark McDonnell, James J. McNally
  • TRICYCLIC DELTA-OPIOID MODULATORS
    Publication number: 20110245291
    Abstract: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ?-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.
    Type: Application
    Filed: June 10, 2011
    Publication date: October 6, 2011
    Inventors: John R. Carson, Ellen Codd, Christine M. Razler, Andrea Works, Mark McDonnell, James J. McNally
  • Thiozanthene derivatives as delta-opioid modulators
    Patent number: 7982042
    Abstract: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ?-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: July 19, 2011
    Assignee: Janseen Pharmacautica NV
    Inventors: John R. Carson, Ellen Codd, Christine M. Razler, Andrea Works, Mark McDonnell, James J. McNally
  • CDNA encoding the human ?2 ?4 calcium channel subunit
    Patent number: 7820792
    Abstract: The present invention provides nucleic acid and polypeptide sequences describing an isoform of the ?2?-4 subunit of a voltage gated calcium channel. The nucleic acids described herein can be used to produce functional ?2?-4 protein. The calcium channel ?2?-4 protein may be isolated for the purposes of binding experiments or may be used in cells to form a functional calcium channel complex.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: October 26, 2010
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Ning Qin, Ellen Codd
  • AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR
    Publication number: 20100125140
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to ?-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Application
    Filed: January 22, 2010
    Publication date: May 20, 2010
    Inventors: Ellen Codd, Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
  • Aminotetralin-derived urea modulators of vanilloid VR1 receptor
    Patent number: 7678812
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to ?-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: March 16, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ellen Codd, Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
  • TRICYCLIC DELTA-OPIOID MODULATORS
    Publication number: 20090298867
    Abstract: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic ?-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.
    Type: Application
    Filed: August 6, 2009
    Publication date: December 3, 2009
    Inventors: John R. Carson, Ellen Codd, Christine M. Razler, Andrea Works, Mark McDonnell, James J. McNally
  • CDNA ENCODING THE HUMAN ALPHA2 DELTA4 CALCIUM CHANNEL SUBUNIT
    Publication number: 20090259022
    Abstract: The present invention provides nucleic acid and polypeptide sequences describing an isoform of the ?2?-4 subunit of a voltage gated calcium channel. The nucleic acids described herein can be used to produce functional ?2?-4 protein. The calcium channel ?2?-4 protein may be isolated for the purposes of binding experiments or may be used in cells to form a functional calcium channel complex.
    Type: Application
    Filed: March 20, 2009
    Publication date: October 15, 2009
    Inventors: Ning Qin, Ellen Codd
  • Tricyclic-bridged piperidinylidene derivatives as 8-opioid modulators
    Patent number: 7589103
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases and conditions, including pain. Such compounds are represented by Formula I as follows: wherein A, Z, Y, R1-R5 are defined herein.
    Type: Grant
    Filed: June 22, 2004
    Date of Patent: September 15, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: John R. Carson, Ellen Codd, Christine M. Razler, Andrea Works, Mark McDonnell, James J. McNally
  • CDNA encoding the human alpha2 delta4 calcium channel subunit
    Patent number: 7524643
    Abstract: The present invention provides nucleic acid and polypeptide sequences describing an isoform of the ?2?-4 subunit of a voltage gated calcium channel. The nucleic acids described herein can be used to produce functional ?2?-4 protein. The calcium channel ?2?-4 protein may be isolated for the purposes of binding experiments or may be used in cells to form a functional calcium channel complex.
    Type: Grant
    Filed: April 11, 2001
    Date of Patent: April 28, 2009
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Ning Qin, Ellen Codd
  • QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR
    Publication number: 20080300236
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Application
    Filed: July 16, 2008
    Publication date: December 4, 2008
    Inventors: Ellen Codd, Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
  • Human voltage gated sodium channel ?1A subunit and methods of use
    Patent number: 7408036
    Abstract: DNAs encoding human voltage gated sodium channel ?1A subunit have been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.
    Type: Grant
    Filed: March 8, 2006
    Date of Patent: August 5, 2008
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Ning Qin, Ellen Codd, Michael D'Andrea
  • AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR
    Publication number: 20080097102
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to ?-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Application
    Filed: October 23, 2007
    Publication date: April 24, 2008
    Inventors: Ellen Codd, Scott Dax, Michele Jetter, Mark McDonnell, James McNally, Mark Youngman
  • Human cyclooxygenase-3 enzyme and uses thereof
    Publication number: 20070166789
    Abstract: The present invention provides nucleic acid and polypeptide sequences describing a novel isozyme of the cyclooxygenase enzyme, herein named as human cyclooxygenase-3. The isolated nucleic acid or polypeptide molecule of the invention can be used in detection assays, gene therapy, and screening assays.
    Type: Application
    Filed: January 10, 2007
    Publication date: July 19, 2007
    Inventors: Ning Qin, Ellen Codd, Christopher Flores, Sui-Po Zhang
  • Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor
    Patent number: 7183411
    Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to naphthol, quinoline and isoquinoline-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: February 27, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Ellen Codd, Scott L. Dax, Michele Jetter, Mark McDonnell, James J. McNally, Mark Youngman
  • CDNA encoding the human ?2 ?4 calcium channel subunit
    Patent number: 7157248
    Abstract: The present invention provides nucleic acid and polypeptide sequences describing a novel isoform of the ?2? subunit of a voltage gated calcium channel, herein named as ?2?-4. The isolated nucleic acid or polypeptide molecule of the invention can be used in diagnosing and treating a disease or disorder associated with a defective ?2?-4 subunit, such as seizure-related syndromes, anxiety, multiple sclerosis, and the like.
    Type: Grant
    Filed: April 10, 2002
    Date of Patent: January 2, 2007
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Ning Qin, Ellen Codd